Dr Kevin Cox
Kevin has over 25 years’ experience in the life science industry, covering a wide range of sectors such as biomanufacturing, anti-infectives development, biomedical imaging, pathology, and clinical pharmacology. Serving as CEO of high growth biotechnology businesses, he has extensive experience in strategy, corporate development, M&A, financing and joint ventures. With a passion for improving translational science, Kevin has developed strong links to government, funding bodies and academia, and has contributed to a number of public sector advisory committees. Kevin currently has non-executive roles with Biorelate Limited, Syndermix SA and the British Neuroscience Association
Dr Suzanne Dilly
Chief Executive Officer
Dr Suzanne Dilly is an experienced entrepreneurial scientist. Trained in medicinal and pharmaceutical chemistry at Loughborough University she moved to the University of Warwick as a postdoctoral researcher in a multi-disciplinary team allowing acquisition of additional expertise in molecular biology and biochemistry.
After commercialising her research in Warwick spin-out, a2sp Limited, Suzanne was awarded a prestigious Royal Society of Edinburgh Enterprise Fellowship, during which formal commercial and entrepreneurial training completed her transition from lab to boardroom. Further recognition was achieved with the award of a finalist’s position in the Innovate UK Women in Innovation Awards (2017). Completing commercial transactions to progress projects through multiple companies, Suzanne has been working in small company virtual biotechs since 2006.
Mr Gerry Desler
Chief Financial Officer
Gerry is a chartered accountant, who qualified in 1968 with a City firm, before becoming a partner in 1970. Between 1985 to 1990 he was the Senior Partner. During his time in the City, he has specialised in consultancy work, much of it involving funding and venture capital.
He was involved in one of the first joint ventures in what was then the People’s Republic of China in 1980. Gerry was previously the Finance Director of Premier Management Holdings plc, an AIM listed company and is on the board of a number of private companies. Gerry also holds positions as Company Secretary at Prospex Oil and Gas Plc both AIM listed companies. (Member of Audit Committee)
Mr Kevin Alexander
Kevin is a qualified solicitor in England and an attorney in New York and he was a partner at major law firms in both London and the United States for over 25 years. Since leaving the law he has been involved in forming and managing various businesses, both private and public. Kevin is a director of Valirx Plc, and joined the board in September 2006. He has an MA in law from Cambridge University.
Mr Martin Lampshire
Martin started his career in Lloyds Bank’s Commercial Services division in 1989 after completing the ACIB qualification. He has over twenty years’ experience in Corporate Broking, working for a number of city-based firms including Teather & Greenwood, Charles Stanley, Hichens Harrison Stockbrokers and Daniel Stewart Stockbrokers.
He has assisted many companies in a variety of equity raises including IPOs, secondary fundraisings, vendor and private placings across a variety of sectors. He has also worked in a number of overseas financial centres including Hong Kong, Singapore, Kuala Lumpur and Dubai. Martin is currently an Executive Director of Global Resources Investment Trust Plc and a Non-Executive Director of Bould Opportunities Plc
Mr Kumar Nawani
Head Of Operations
Kumar has been working over 20 years in international trade, client & vendor management, business development, brand development, e-commerce, procurement, IT management & compliance roles with established public and private companies here in the UK and previously in Hong Kong. Kumar has been with Valirx and its group of companies since January 2008 and has actively been part of the Valirx management team since it’s pre-clinical development phases of it’s core assets.
Mr Mark Treharne
Corporate Development Manager
Mark began his career in the City in 2011 and has gained 9 years of experience in Corporate Broking and Equity sales working for numerous different firms including Daniel Stewart, Northland Capital Partners and Pello Capital. He has assisted many companies in capital raising across that time. Mark also has 4 years of experience working for Valirx having worked for the company since 2016. His expertise will be put to use by the company in rebuilding the reputation of the company within the City and working closely with City firms to identify potentially interesting assets for the Valirx portfolio of Companies.